An updated research focus on the employment of computer-aided drug discovery and repurposing techniques for the identification and evaluation of SARS-CoV-2 Main protease inhibitors: A protocol for a systematic review and meta-analysis

1. Introduction

The emergence of COVID-19 caused by SARS-CoV-2 has resulted in significant global morbidity and mortality, with over 680 million confirmed cases and 6,805,012 deaths as of March 05, 2023 (https://www.worldometers.info/coronavirus/) (1). The virus is transmitted through various means including direct contact, droplets, airborne, fomite, fecal-oral, bloodborne, sexual intercourse, ocular, mother-to-child, and animal-to-human, posing challenges in controlling its spread (2). Patients with underlying conditions are at higher risk of severe disease. Additionally, asymptomatic infections can also transmit the virus to others, making control of its spread challenging (3,4).

Currently, there are no globally approved specific antiviral drugs or vaccines for COVID-19, and treatment primarily relies on symptomatic and oxygen therapy (5,6). Mechanical ventilation is recommended for respiratory failure, and intensive care is needed for complicated disease (7,8).

Various drugs such as Chloroquine, Hydroxychloroquine, Lopinavir, Ritonavir, Nafamostat, Camostat, Famotidine, Umifenovir, Nitazoxanide, Ivermectin, Corticosteroids, Tocilizumab, Sarilumab, Bevacizumab, And Fluvoxamine) are under clinical trial (9,10), including antivirals (Bemcentinib, Chloroquine & Hydroxychloroquine, Lopinavir boosted with Ritonavir and Remdesivir) (11,12) and immune modulators (Anakinra And Canakinumab, Azithromycin, Brensocatib, Convalescent Plasma, Corticosteroids, Interferon Beta, Ruxolitinib, Mesenchymal Stromal Cells And Sarilumab And Tocilizumab), with a combination of drugs (noscapine and hydroxychloroquine) showing promise for their strong binding affinity to SARS-CoV-2 Mpro(13,14). However, solid clinical trials are reportedly more difficult to conduct due to increased public inquiry regarding readily available drugs. (15).

Designing drugs that directly target conserved enzymes like main protease or 3C-like protease (Mpro or 3CLpro), papain-like protease (PLpro), non-structural protein 12 (nsp12), and RNA-dependent RNA polymerase (RdRP) could be broad-spectrum and effective(18–21). Remdesivir, an antiviral targeting RdRP, has shown a therapeutic role in shortening recovery time for adult COVID-19 patients, but its effect on severely ill patients is uncertain(16,17).

Multiple studies are currently underway to identify SARS-CoV-2 Mpro inhibitors using structure-based, virtual, and high-throughput screening methods (22–26). Summarizing the results of these studies, identifying their gaps, and appraising critiques are crucial to putting forward strong recommendations and future directions (27). This review will provide an overview of recent advancements and prospects of structure-based drug designing activities targeting SARS-CoV-2 Mpro, which is critical for developing potential drugs that can halt infection and disease progression. The authors will emphasize the importance of continued literature review and consideration of the latest evidence, particularly in the rapidly evolving pandemic landscape and prioritize the development of evidence-based clinical practice guidelines and public health policies.

In its primary objective, this review will assess the existing research on the use of computational approaches for drug repurposing in the context of COVID-19. This study will provide evidence-based information and conduct a comprehensive analysis of the computer-aided drug discovery and repurposing of the SARS-CoV-2 Main protease inhibitors, thereby producing a high-quality synthesis of information. The study will also explore potential innovative therapeutic applications for preventing or treating the novel viral infection by the inhibition of the Main Protease. In addition, this review will highlight research gaps in the treatment of COVID-19 and provide suggestions for future research.

Systematic review framework

The present review will adopt the framework initially proposed by Arksey and O’Malley (28,29) and subsequently refined by Levac et al. (2010), as illustrated in Table 1 (28–31). This framework comprises six distinct steps; however, the final step concerning expert/stakeholder consultation will not be pursued in this review due to financial limitations. To supplement this omission, grey literature sources will be utilized to broaden the scope of information, perspectives, and applicability. In line with the revised framework, the review incorporates enhancements proposed by Levac et al. to optimize the rigor and comprehensiveness of the analysis.

1. Identify the research questions

To accomplish the aims and objectives of this review, a series of research questions have been formulated to provide guidance. The primary research question is articulated as follows: What is the current state of research in computer-aided drug discovery and repurposing of SARS-CoV-2 main protease inhibitors, and what are the potential research gaps and opportunities for further investigation?

The review aims assess the existing research on the use of computational approaches for drug repurposing in the context of COVID-19. This study will provide evidence-based information and explore potential innovative therapeutic applications for preventing or treating the novel viral infection by the inhibition of the Main Protease.

To accomplish the study’s objective, the following research questions will be explored:

1. What are the primary sources, potential inhibitors and data types utilized in computer-aided drug discovery and repurposing for the identification of SARS-CoV-2 main protease inhibitors?

2. How do different computational tools and techniques contribute to the identification of potential SARS-CoV-2 main protease inhibitors?

3. What is the safety and efficacy profile of the SARS-CoV-2 main protease inhibitors identified through computational methods in pre-clinical and clinical studies?

4. What are the potential research gaps and areas for further investigation directions in computer-aided drug discovery and repurposing of SARS-CoV-2 main protease inhibitors?

5. What are the limitations and challenges of using computer-aided drug discovery for SARS-CoV-2 Main protease inhibitors repurposing?

Eligibility of research questions

The questions have been used to break down searchable keywords using the Population, Intervention, Comparison, and Outcomes (PICO) framework (32,33). Therefore, the PICO framework for the study can be defined as follows:

This review will be drafted according to the PRISMA Flow diagram. The present protocol will be submitted to PROSPERO.

2. Identify relevant studies

Relevant literature will be searched from the following databases: PubMed; EBSCOhost (the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and MEDLINE); Google Scholar; Cochrane Library, ScienceDirect, Web of Science, Scopus,WILEY online Library, the WHO Global Health Library and grey literature. Reference lists of included studies will also be searched. The keywords search will include the following: "SARS-CoV-2 Main protease inhibitors", "Computer aided drug discovery", "Repurposing", "Virtual screening", "Docking", "Molecular dynamics", "QSAR", "Machine learning". The Boolean search terms (AND and OR) and Medical Subject Headings (MeSH) related to computer-aided drug discovery, repurposing, SARS-CoV-2, main protease inhibitors, and related terms.

The search will include articles published from March 2020 to the present. Peer review studies and grey literature reporting on evidence of computer aided drug discovery and repurposing of the SARS-CoV-2 Main protease inhibitors will be included. In case of missing studies or additional information, primary study or review authors will be contacted for further details. Non-responsive authors will lead to the exclusion of their publications.

3. Select the study

Search strategy

The researchers will conduct a comprehensive and systematic literature search in several databases. The search strategy will involve the following databases: PubMed; EBSCOhost (the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and MEDLINE); Google Scholar; Cochrane Library, ScienceDirect, Web of Science, Scopus,WILEY online Library, the WHO Global Health Library and grey literature. The search strategy will employ various keywords and search terms such as "SARS-CoV-2 Main protease inhibitors", "Computer aided drug discovery", "Repurposing", "Virtual screening", "Docking", "Molecular dynamics", "QSAR", "Machine learning", "Novel coronavirus," "COVID-19," and "SARS-CoV-2" to identify relevant articles. Additionally, search terms related to drug repurposing such as "Antiviral agents," "Drug therapy," "Therapeutic agents," "Virtual screening," "molecular docking," "molecular modelling," "molecular dynamic," and "computational" will also be included.

To account for potential delays in database indexing, we will conduct a comprehensive search for relevant literature by utilizing selected infectious disease journals. In addition, we will access the official websites of reputable organizations, such as the World Health Organization (https://www.who.int/), the Centres for Disease Control and Prevention (https://www.cdc.gov/), the European Centre for Disease Prevention and Control (https://www.ecdc.europa.eu/en), and Public Health England (PHE) (https://www.gov.uk/government/organisations/public-health-england). We will also search relevant preprint servers, including BioRxiv (https://www.biorxiv.org/), ChemRxiv (https://chemrxiv.org/), medRxiv (https://www.medrxiv.org/), and SSRN (https://www.ssrn.com/index.cfm/en/), and conduct a thorough review of the reference lists of all relevant studies to identify additional reports. The search results will then be exported to EndNote Version 20 for further analysis.

The systematic review will comprise original research articles in English and French that pertained to biocomputational methods utilized in the context of repurposing drugs for SARS-CoV-2. The eligible studies will be required to emphasize drugs or compounds with an effect on the Main Protease (M^Pro) that had been investigated by the research community.

The search strategy for this review aims to be comprehensive to identify both published and unpublished (grey literature) primary studies and reviews (33–35). A preliminary exploration was performed using the database findings found in Appendix 1. A three-stage exploration plan will be employed. The first step involves conducting an initial constrained exploration of the electronic databases. This primary exploration will be supervised, exported to the Endnote 20 reference manager for screening of abstracts and full articles. Repetitive articles will be removed. A second exploration utilizing all recognized keywords and index terms will then be conducted across all included databases. Finally, the reference catalog of all recognized reports and articles will be reviewed for additional studies (34). For screening of abstracts and full articles, the Endnote library will be shared with a second reviewer. Based on the aforementioned criteria, the authors will conduct independent title and abstract screenings and then perform a detailed review of relevant articles. In the event of a disagreement, the authors will discuss the reasons behind their respective viewpoints to reach a consensus. If they are unable to reach an agreement, a third author will be consulted to resolve the differing opinions until consensus is reached (36–39).

To ensure transparency in the selection process, a PRISMA Flow Diagram will be followed at each phase of the selection process (refer to Figure 1). Furthermore, a list of studies that were excluded during the full-text review will be documented as an appendix, with concise explanations for their exclusion (28,40).

• Download figure
• Open in new tab

Fig 1:

Schematic illustration of prevalent computational methods utilized for inhibition design of SARS-CoV-2 Main Protease (MPro)

• Download figure
• Open in new tab

Figure 2:

The PRISMA Flow Diagram for the scoping review screening process (28)

4. Chart the data

We will conduct data extraction to enable a logical and descriptive summary of the search results presented in an Appendix 1 (28). At this stage, a table of characteristics for included studies will be developed to record key information such as author, reference, and results or findings relevant to the review question/s, as outlined in an Appendix. This table may be refined further during the review process, and the sample extraction form will be updated accordingly. Using the key information chart, data from selected articles will be extracted and synthesized differently for interpretation to identify key findings.

5. Collate, summarize and report the results

The review will include a comprehensive search of several electronic databases, and it is anticipated that a large number of relevant studies will be identified. A summary will be provided alongside tabulated and/or charted results, which will describe how they relate to the review objective and question/s. The search will be conducted using a combination of keywords related to SARS-CoV-2, main protease inhibitors, and computational drug discovery techniques. The identified studies will be screened by two independent reviewers based on the predefined inclusion and exclusion criteria. Following the screening process, the included studies will undergo data extraction and quality assessment. The data extracted will include details on the computational methods used, the identified compounds, and their potency in inhibiting the main protease. The quality of the included studies will be assessed using standardized tools. The meta-analysis component of the study will involve pooling the data from the included studies and conducting statistical analyses to evaluate the efficacy of the identified inhibitors. The outcomes of interest will include measures of inhibitory potency, such as IC50 or Ki values, as well as any adverse effects reported in the studies. It is expected that the results of this systematic review and meta-analysis will provide a comprehensive and up-to-date overview of the research on the employment of computer-aided drug discovery and repurposing techniques for the identification and evaluation of SARS-CoV-2 main protease inhibitors. The findings may reveal potential inhibitors that have not yet been identified through traditional drug discovery methods and could serve as a starting point for the development of new treatments for COVID-19. In summary, the results of this study are anticipated to provide valuable insights into the use of computational methods for drug discovery and repurposing and their potential in identifying effective treatments for COVID-19. The findings of the review will be disseminated through a peer-reviewed publication and conference presentations.

Synthesis

This process will employ a rigorous approach to combine and interpret the results of the selected studies, while also identifying and addressing potential sources of bias or variability. The review team will extract relevant data from the selected studies and combine them into a single dataset suitable for meta-analysis. To account for potential sources of variability across studies, the review team will conduct subgroup analyses based on relevant study characteristics such as study design, patient population, intervention type, and outcome measures. The results of these subgroup analyses will be compared and synthesized to provide an overall estimate of treatment effect for the primary outcome. Finally, the review team will interpret the results of the meta-analysis in light of the available evidence and discuss the implications/ potential impact of the findings for future research, clinical practice and policies. The findings will be presented in a clear and transparent manner to facilitate interpretation and decision-making by relevant stakeholders.

Conclusion

Based on the current research, this systematic review will provide a comprehensive and up-to-date overview of the SARS-CoV-2 Main protease literature available as of May 2023, revealing a consistent rise in the number of published or online articles since the initial outbreak. The review will include the strengths and limitations of different methodologies and the potential implications for the development of effective treatments for COVID-19. The findings of this review will contribute to the advancement of our understanding of the use of computational methods in drug discovery and repurposing, and may ultimately help to accelerate the development of new therapeutic agents. However, the review will also highlights a paucity of diversity in the types of studies conducted, particularly in the domain of clinical research. In light of the rapidly evolving pandemic landscape, the authors stress the crucial need for continuous literature review and consideration of the latest evidence. Additionally, they urge researchers to avoid redundant efforts and prioritize the development of evidence-based clinical practice guidelines and public health policies.